Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec ...

Recursion Pharmaceuticals Inc （纳斯达克：RXRX）董事Christopher Gibson于2026年1月20日以每股4.47美元的价格出售了40,000股A类普通股，总计178,800美元。

AI 制药上市公司 Recursion（NASDAQ: RXRX）宣布与英伟达（NVIDIA）建立了合作伙伴关系，并获得英伟达 5000 万美元的投资。 AI 制药上市公司 Recursion（NASDAQ: RXRX）宣布与英伟达（NVIDIA）建立了合作伙伴关系，并获得英伟达 5000 万美元的投资。 达成协议后，两家公司计划 ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 4.64% at $4.73. The stock's performance was behind the ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on r/stocks by Antique-Reference585. In this article, we ...

Recursion Pharmaceuticals (RXRX) closed at $4.65 in the latest trading session, marking a -4.12% move from the prior day.

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

It’s got all the correct buzzwords for a hot biotech stock: machine learning, cell images, artificial intelligence. When Recursion Pharmaceutical went public at $18/share back in April, the stock ...

Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...